Skip to main content
Premium Trial:

Request an Annual Quote

Roche Posts Flat MDx Sales

NEW YORK (GenomeWeb News) – Roche today reported flat molecular diagnostics sales for the first nine months of 2013 compared to the first nine months of 2012.

The Swiss pharmaceuticals, diagnostics, and research products firm posted overall sales of CHF 34.87 billion ($38.63 billion) for the nine months ended Sept. 30, up 3 percent from CHF 33.69 for the first nine months of 2012.

Its diagnostics sales were up 2 percent to CHF 7.68 billion from CHF 7.50 billion.

Within the Diagnostics Division, the firm's molecular diagnostics sales were flat year over year at CHF 1.19 billion, but up 2 percent at constant exchange rates. Roche said that MDx sales were driven by its human papillomavirus tests, real-time qPCR reagents, and oncology companion diagnostic tests. Growth, however, was offset by declines in the firm's sequencing business.

As reported by GenomeWeb Daily News earlier this week, Roche is shutting down its 454 Life Sciences sequencing operations and laying off about 100 employees. The firm said the 454 sequencers will be phased out by mid-2016.

Roche, however, is not exiting the genomic sequencing market. Last month it forged a deal for up to $75 million with Pacific Biosciences to develop diagnostic products based on PacBio's SMRT technology.

Sales for Roche's Pharmaceutical division climbed 4 percent year over year to CHF 27.19 billion from CHF 26.20 billion.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more